ProCE Banner Activity

SIMPLIFY-2: Momelotinib vs Best Available Therapy in Ruxolitinib-Experienced Pts With Myelofibrosis

Slideset Download
Conference Coverage
Results from this phase III study reveal comparable splenic response rate but improved symptomatic response and transfusion independence rates with momelotinib vs BAT.

Released: June 09, 2017

Expiration: June 08, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology